But no plain bowtie2-build (the -l is for 64-bit indexes but they are not supported by TopHat as yet)?
-
-
No, I have a plain bowtie2-build as well.Comment
-
I am stumped.
Give a real sample a try to see if that works.Comment
-
Damn =P I'll do that and see if it works. Thanks for all your help, regardless!Comment
-
Downgrading to Bowtie 2.2.2 did the trick! Must have been a bug or something in 2.2.3...Comment
-
I was using Bowtie 2.2.1. Won't upgrade to 2.2.3.Comment
-
Error in testing the installation of Tophat
I'm a brand new person in RNA-Seq and a beginner in bioinformatics as well. So my apologies if my question is naïve or it has been posted already. Recently I installed Tophat v2.0.12, with Bowtie, SAMtools and Boost libraries, in Ubuntu 12.04 lts 32-bits. However when I tried to test the installation
tophat -r 20 test_ref reads_1.fq reads_2.fq
I got this error:
[2014-07-04 10:52:25] Beginning TopHat run (v2.0.12)
-----------------------------------------------
[2014-07-04 10:52:25] Checking for Bowtie
Bowtie 2 not found, checking for older version..
Error: TopHat requires Bowtie 0.12.9 or later
It seems to me there is a problem with the version of bowtie I have installed, perhaps to old? If you could please give some clue about how to solve this problem?
Thanks in advancedComment
-
If you only have bowtie (v.1.x) installed then you may need to add the following optionOriginally posted by lamaga View Post
It may be better to install bowtie2 (http://sourceforge.net/projects/bowt...les/bowtie2/)?Code:$ tophat --bowtie1 -r 20 test_ref reads_1.fq reads_2.fq
Or it may be a simple fix of adjusting your $PATH so bowtie directories are included there.Last edited by GenoMax; 07-06-2014, 06:21 AM.Comment
-
You need the newest version of tophat
TopHat 2.0.12 release 6/24/2014
Version 2.0.12 is a maintenance release with the following simple fix:
This version is compatible with Bowtie2 v2.2.3.Comment
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM
Comment